SG11201906422VA - Apoc-ii mimetic peptides - Google Patents
Apoc-ii mimetic peptidesInfo
- Publication number
- SG11201906422VA SG11201906422VA SG11201906422VA SG11201906422VA SG11201906422VA SG 11201906422V A SG11201906422V A SG 11201906422VA SG 11201906422V A SG11201906422V A SG 11201906422VA SG 11201906422V A SG11201906422V A SG 11201906422VA SG 11201906422V A SG11201906422V A SG 11201906422VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- delta
- gatehouse
- rockville
- suite
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1722—Plasma globulins, lactoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Marine Sciences & Fisheries (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762448358P | 2017-01-19 | 2017-01-19 | |
| US201762476535P | 2017-03-24 | 2017-03-24 | |
| US201762476531P | 2017-03-24 | 2017-03-24 | |
| PCT/US2018/014532 WO2018136803A1 (en) | 2017-01-19 | 2018-01-19 | Apoc-ii mimetic peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201906422VA true SG11201906422VA (en) | 2019-08-27 |
Family
ID=62908746
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201906422VA SG11201906422VA (en) | 2017-01-19 | 2018-01-19 | Apoc-ii mimetic peptides |
| SG10201911974UA SG10201911974UA (en) | 2017-01-19 | 2018-01-19 | Apoc-ii mimetic peptides |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201911974UA SG10201911974UA (en) | 2017-01-19 | 2018-01-19 | Apoc-ii mimetic peptides |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11136372B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3571216B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7353973B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102700862B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN110831957B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018210404B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019014707A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3050106A1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL268093B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2019008529A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ755599A (cg-RX-API-DMAC7.html) |
| SG (2) | SG11201906422VA (cg-RX-API-DMAC7.html) |
| TW (2) | TW202130652A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018136803A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11136372B2 (en) | 2017-01-19 | 2021-10-05 | The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services | ApoC-II mimetic peptides |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240309065A1 (en) * | 2021-06-23 | 2024-09-19 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Short apoc-ii mimetic peptides and methods of use |
| CN119233984A (zh) * | 2022-05-05 | 2024-12-31 | 美国政府(由卫生和人类服务部的部长所代表) | 短载脂蛋白e模拟肽及其使用方法 |
| US20240043499A1 (en) * | 2022-08-07 | 2024-02-08 | Protean Bio, Inc. | Peptides for beta-cell survival and insulin production |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US6156727A (en) * | 1996-09-05 | 2000-12-05 | Uab Research Foundation | Anti-atherosclerotic peptides and a transgenic mouse model of antherosclerosis |
| NZ532217A (en) | 2001-09-28 | 2006-12-22 | Esperion Therapeutics Inc | Use of an alpha helical apolipoprotein or HDL associating protein adapted to be administered locally to prevent or reduce stenosis or restenosis or to stabilize a plaque |
| US7220576B2 (en) * | 2002-01-07 | 2007-05-22 | Lifesensors, Inc. | Methods and compositions for protein expression and purification |
| CA2512879A1 (en) * | 2003-01-17 | 2004-08-12 | Soumya P. Sahoo | N-cyclohexylaminocarbonyl benzenesulfonamide derivatives |
| EP1706131A4 (en) * | 2003-12-15 | 2009-08-12 | Univ California | THE CELLULAR CHOLESTEROL EFFLUX STIMULATING HELICULAR SYNTHETIC PEPTIDES |
| AU2005214225B2 (en) * | 2004-02-19 | 2010-05-20 | Banyu Pharmaceutical Co., Ltd. | Novel sulfone amide derivative |
| JP5048486B2 (ja) * | 2004-07-16 | 2012-10-17 | トラスティーズ オブ タフツ カレッジ | アポリポタンパク質a1の模倣物とその使用 |
| AU2006263332B2 (en) * | 2005-06-29 | 2012-02-23 | Hadasit Medical Research Services & Development Ltd. | Protein kinase C inhibitors for prevention of insulin resistance and type 2 diabetes |
| US20080138284A1 (en) * | 2006-09-26 | 2008-06-12 | Lipid Sciences, Inc. | Novel Peptides That Promote Lipid Efflux |
| WO2009097584A1 (en) * | 2008-01-30 | 2009-08-06 | Proteogenix, Inc. | Maternal serum biomarkers for detection of pre-eclampsia |
| WO2009129263A1 (en) * | 2008-04-15 | 2009-10-22 | The Government Of The Usa As Represented By The Secretary Of The Department Of Health & Human Serv. | Peptides promoting lipid efflux via abca1 and activating a lipoprotein lipase |
| CN102753576A (zh) * | 2009-09-30 | 2012-10-24 | 首尔大学教产学协力团 | 载脂蛋白a-1模拟肽以及包含其的用于治疗高血脂及高血脂相关疾病的治疗剂 |
| US10087234B2 (en) | 2012-11-06 | 2018-10-02 | Les Hopitaux Universitaires De Geneve | Mimetic peptides |
| AU2018210404B2 (en) | 2017-01-19 | 2022-01-27 | Novo Nordisk A/S | ApoC-II mimetic peptides |
| EA201991491A1 (ru) | 2017-03-24 | 2019-12-30 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сервисис | Миметические пептиды apoc-ii |
-
2018
- 2018-01-19 AU AU2018210404A patent/AU2018210404B2/en active Active
- 2018-01-19 WO PCT/US2018/014532 patent/WO2018136803A1/en not_active Ceased
- 2018-01-19 TW TW109138699A patent/TW202130652A/zh unknown
- 2018-01-19 EP EP18742118.5A patent/EP3571216B1/en active Active
- 2018-01-19 KR KR1020197024024A patent/KR102700862B1/ko active Active
- 2018-01-19 NZ NZ755599A patent/NZ755599A/en unknown
- 2018-01-19 JP JP2019539809A patent/JP7353973B2/ja active Active
- 2018-01-19 TW TW107102123A patent/TWI788323B/zh active
- 2018-01-19 SG SG11201906422VA patent/SG11201906422VA/en unknown
- 2018-01-19 BR BR112019014707-1A patent/BR112019014707A2/pt unknown
- 2018-01-19 IL IL268093A patent/IL268093B2/en unknown
- 2018-01-19 CA CA3050106A patent/CA3050106A1/en active Pending
- 2018-01-19 SG SG10201911974UA patent/SG10201911974UA/en unknown
- 2018-01-19 MX MX2019008529A patent/MX2019008529A/es unknown
- 2018-01-19 CN CN201880019604.7A patent/CN110831957B/zh active Active
- 2018-01-19 US US16/479,183 patent/US11136372B2/en active Active
-
2020
- 2020-12-29 IL IL279831A patent/IL279831A/en unknown
-
2021
- 2021-03-09 US US17/195,766 patent/US11827690B2/en active Active
-
2023
- 2023-06-19 JP JP2023100171A patent/JP2023116739A/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11136372B2 (en) | 2017-01-19 | 2021-10-05 | The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services | ApoC-II mimetic peptides |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190121305A (ko) | 2019-10-25 |
| IL268093B1 (en) | 2024-03-01 |
| TW202130652A (zh) | 2021-08-16 |
| CN110831957A (zh) | 2020-02-21 |
| WO2018136803A8 (en) | 2019-08-01 |
| EP3571216B1 (en) | 2026-05-27 |
| US20210324043A1 (en) | 2021-10-21 |
| US11827690B2 (en) | 2023-11-28 |
| JP7353973B2 (ja) | 2023-10-02 |
| US11136372B2 (en) | 2021-10-05 |
| AU2018210404B2 (en) | 2022-01-27 |
| WO2018136803A1 (en) | 2018-07-26 |
| JP2023116739A (ja) | 2023-08-22 |
| TW201835097A (zh) | 2018-10-01 |
| AU2018210404A1 (en) | 2019-08-08 |
| SG10201911974UA (en) | 2020-02-27 |
| CN110831957B (zh) | 2024-02-09 |
| KR102700862B1 (ko) | 2024-08-30 |
| EP3571216C0 (en) | 2026-05-27 |
| NZ755599A (en) | 2022-12-23 |
| TWI788323B (zh) | 2023-01-01 |
| EP3571216A4 (en) | 2020-11-04 |
| IL279831A (en) | 2021-03-01 |
| CA3050106A1 (en) | 2018-07-26 |
| BR112019014707A2 (pt) | 2020-04-07 |
| IL268093B2 (en) | 2024-07-01 |
| JP2020511425A (ja) | 2020-04-16 |
| US20200140522A1 (en) | 2020-05-07 |
| IL268093A (en) | 2019-09-26 |
| EP3571216A1 (en) | 2019-11-27 |
| MX2019008529A (es) | 2020-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908391XA (en) | Methods for modulating an immune response | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201903454VA (en) | Immunologically discernible cell surface variants for use in cell therapy | |
| SG11201910096RA (en) | Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201909081YA (en) | Anti-ilt4 antibodies and antigen-binding fragments | |
| SG11202000105QA (en) | Anti-cd166 antibodies and uses thereof | |
| SG11201903021WA (en) | Anti-human 4-1 bb antibodies and use thereof | |
| SG11201806992VA (en) | Antibodies to tigit | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201901020RA (en) | Anti-siglec-7 antibodies for the treatment of cancer | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
| SG11201907754RA (en) | Anti-phf-tau antibodies and uses thereof | |
| SG11201908420WA (en) | Compositions of plinabulin and use thereof | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201809336QA (en) | Anti-pd-l1 antibodies | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201908051RA (en) | Modified human igm constant regions for modulation of complement-dependent cytolysis effector function | |
| SG11201810466PA (en) | Compositions and methods related to engineered fc constructs | |
| SG11201907505TA (en) | Low-viscosity, high-concentration evolocumab formulations and methods of making the same | |
| SG11201903287PA (en) | Anti-respiratory syncytial virus antibodies, and methods of their generation and use | |
| SG11201806342SA (en) | Glucagon and glp-1 co-agonists for the treatment of obesity | |
| SG11201407579QA (en) | Interleukin-2 fusion proteins and uses thereof | |
| SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof |